Clinical Trials

Pancreatic Neoplasms

NCT05011227 2024-03-06

Camrelizumab and Chemotherapy Combined With Endoscopic Surgery for Recurrent Nasopharyngeal Carcinoma

100 enrolled

Nasopharyngeal Carcinoma

NCT06235164 2024-01-31

The Safety and Efficacy of Neoadjuvant Immunochemotherapy Followed by Laparoscopic Gastrectomy for Gastric Cancer

Unknown

585 enrolled

Locally Advanced Gastric Cancer

NCT05062837 2024-01-23

Hepatectomy Combined With Camrelizumab and Apatinib in CNLC Stage IIIb HCC

Phase 2/3 Unknown

62 enrolled

Carcinoma, Hepatocellular

NCT04395989 2023-12-22

FUTURE-SUPER

139 enrolled

Triple Negative Breast Neoplasms

NCT06170697 2023-12-20

Advanced First-line Treatment of Short-term Postoperative Progression of Head and Neck Squamous Cell Carcinoma

46 enrolled

Squamous Cell Carcinoma of Head and Neck

NCT05031949 2023-12-19

CCGLC-003

Phase 1 Unknown

20 enrolled

Carcinoma, Hepatocellular

NCT04559607 2023-12-18

TACE Combined With Camrelizumab and Apatinib in Intermediate and Advanced Hepatocelluar Carcinoma

188 enrolled

Carcinoma, Hepatocellular

NCT06140732 2023-11-20

Apatinib Combined With Camrelizumab in Treating Participants With Advanced Chordoma

30 enrolled

Sarcoma

Chordoma

NCT06031597 2023-09-13

Radiotherapy Combined With ICIs as Treatment for LA-NSCLC After Failing Induction Immunochemotherapy

Phase 3 Unknown

105 enrolled

Carcinoma, Non-Small-Cell Lung, Radiation Pneumonitis

NCT05099848 2023-08-15

A Trial of Conversion Treatment of HAIC Combined With Camrelizumab and Apatinib for Unresected Hepatocellular Carcinoma

21 enrolled

Carcinoma, Hepatocellular

NCT04156698 2023-08-09

Induction Chemotherapy Combined With Immunotherapy for Locally Advanced Hypopharyngeal Carcinoma

51 enrolled

Hypopharyngeal Neoplasms

NCT05928780 2023-07-03

An Umbrella Trial Based on Molecular Pathway for Patients With Metastatic TNBC in First-line Treatment (FUTURE-Trop2)

125 enrolled

Triple Negative Breast Neoplasms

NCT04221516 2023-06-18

Camrelizumab After Completion of Radiotherapy for Oligometastatic Nasopharyngeal Carcinoma

52 enrolled

Nasopharyngeal Carcinoma

NCT04930315 2023-06-13

CAPT

78 enrolled

Carcinoma, Hepatocellular

NCT04586088 2023-05-06

Apatinib and Camrelizumab in Recurrent or Metastatic Nasopharyngeal Carcinoma With First-line Treatment Failure

58 enrolled

Nasopharyngeal Carcinoma

NCT04609176 2023-04-21

Study of Camrelizumab (SHR-1210) and Apatinb Based Therapies for Alpha-fetoprotein (AFP)-Producing Gastric Cancer or Gastroesophageal Junction Adenocarcinoma

64 enrolled

Stomach Neoplasms

NCT04454905 2023-04-19

Camrelizumab in Combination With Apatinib in Advanced ICC: A Single-arm Phase II Study

50 enrolled

Cholangiocarcinoma

NCT04303741 2023-04-12

A Phase II Trial of Camrelizumab in Combination With Apatinib and Eribulin in Patients With Advanced TNBC

46 enrolled

Breast Neoplasms

NCT05556200 2023-04-12

A Phase II Trial of Camrelizumab in Combination With Apatinib for Neoadjuvant Treatment of Early-stage TNBC With a High Proportion of TILs

58 enrolled

Breast Neoplasms, Triple Negative Breast Neoplasms

NCT04443309 2023-03-29

Lenvatinib in Combination With Camrelizumab as First-Line Therapy in Patients With Advanced HCC

53 enrolled

Carcinoma, Hepatocellular

NCT05048017 2023-03-29

Regorafenib Combined With PD-1 Inhibitor Therapy for Second-line Treatment of Hepatocellular Carcinoma

20 enrolled

Carcinoma, Hepatocellular

NCT05097209 2023-03-23

Camrelizumab for the Treatment of Locally Advanced Nasopharyngeal Carcinoma

200 enrolled

Nasopharyngeal Carcinoma

NCT05670925 2023-02-28

A Trial Exploring the Opportune Administration of Nab-paclitaxel in the First Line Treatment, Camrelizumab Combined With Nab-paclitaxel and Famitinib, of TNBC.

46 enrolled

Triple Negative Breast Neoplasms

NCT05742750 2023-02-24

A Phase Ib/II Clinical Study of Camrelizumab and Apatinib Plus GP in the Treatment of Advanced Biliary Tract Cancer

48 enrolled

Biliary Tract Neoplasms

NCT05724355 2023-02-13

CDK4/6 Inhibitor Plus Camrelizumab for PD-1 Inhibitor Refractory R/M NPC

32 enrolled

Nasopharyngeal Carcinoma

NCT05549466 2023-02-08

Targeted or Chemotherapy Combined With Immunotherapy Versus Chemotherapy for PD-1 Inhibitor Refractory R/M NPC

84 enrolled

Nasopharyngeal Carcinoma

NCT05050760 2023-01-31

DCF Combined With Camrelizumab in the Treatment of Esophageal Cancer

55 enrolled

ESCC

NCT05697237 2023-01-25

Carlizumab Plus Sovantinib in Second-line Treatment of Advanced or Metastatic Cholangiocarcinoma

60 enrolled

Cholangiocarcinoma

NCT05669807 2023-01-03

Camrelizumab Combined With Irinotecan or Albumin Paclitaxel for Second-line Treatment of Advanced Gastric Cancer

184 enrolled

Second Line Treatment of Gastric Cancer

NCT05650216 2022-12-14

Camrelizumab Combined With Neoadjuvant Concurrent Chemoradiotherapy for Resectable Locally Advanced ESCC（NICE-RT）

50 enrolled

Esophageal Squamous Cell Carcinoma

NCT05637268 2022-12-05

Carrelizumab Combined With Chemotherapy for Adjuvant Therapy of Esophageal Squamous Cell Carcinoma

23 enrolled

Esophageal Neoplasms

NCT04459078 2022-12-02

Clinical Study of Camrelizumab Combined With APatinib and Albumin Paclitacxel in Patients With Advanced Lung Adenocarcinoma

63 enrolled

Adenocarcinoma of Lung

NCT05051865 2022-11-17

To Explore the Efficacy and Safety of Camrelizumab Combined With SHR1020 in the Treatment of Advanced Melanoma

60 enrolled

Dermatologic

Melanoma

NCT04211090 2022-11-16

CAP-BRAIN

45 enrolled

CNS

Brain Neoplasms

NCT05611463 2022-11-10

CHANCE

25 enrolled

Squamous Cell Carcinoma of Head and Neck

NCT05559008 2022-11-09

A Umbrella Study in R/R PTCL Guided by Molecular Subtypes

116 enrolled

Lymphoid

Lymphoma, T-Cell, Peripheral

NCT04848454 2022-10-18

Efficacy and Safety of Combinition of Camrelizumab in Second-line Neoadjuvant Chemotherapy and Adjuvant Therapy

30 enrolled

HER2-negative Breast Cancer

NCT05564897 2022-10-04

Oncolytic Adenovirus Combined With PD-1 Inhibitor in Patients With Non-muscle-invasive Bladder Cancer

25 enrolled

Genitourinary

Urinary Bladder Neoplasms

NCT05545436 2022-09-22

Carrelizumab (PD-1) Combined With Chemotherapy in Neoadjuvant Treatment of Locally Advanced Gastric Cancer

34 enrolled

Locally Advanced Gastric Cancer

NCT05532527 2022-09-08

NSCLC

35 enrolled

Carcinoma, Non-Small-Cell Lung

NCT03805399 2022-08-10

FUTURE

140 enrolled

Triple Negative Breast Neoplasms

NCT05476380 2022-07-27

Neoadjuvant Therapy of Camrelizumab Combined With Chemotherapy for Resectable Locally Advanced Esophageal Squamous Cell Carcinoma

39 enrolled

Esophageal Neoplasms

NCT04355858 2022-07-26

MULAN

319 enrolled

Breast Neoplasms, Neoplasm Metastasis

NCT04866862 2022-07-25

Fruquitinib Combined With Camrelizumab in Non MSI-H/dMMR Refractory Colorectal Cancer

32 enrolled

Colorectal Neoplasms

NCT05472467 2022-07-25

IMCORT-2

35 enrolled

Carcinoma, Non-Small-Cell Lung

NCT05461235 2022-07-18

Anti-PD-1 Antibody Combined With Autologous DC and NK Cells in the Treatment of Digestive Carcinoma

1 enrolled

PD-1 Antibody

NCT05441254 2022-07-08

Camrelizumab Combined With Intraperitoneal Infusion of Nab-paclitaxel, Intravenous Chemotherapy and S-1 in the Treatment of Advanced Gastric Cancer With Peritoneal Metastasis：Single-arm, Prospective Clinical Study

33 enrolled

Stage IV Gastric Cancer With Metastasis

NCT05438706 2022-06-30

A Clinical Study of the Efficacy and Safety of Chidamide in Combination With Camrelizumab and Carboplatin or Capecitabine in the Second and Third Line Treatment of Relapsed/Metastatic Triple-negative Breast Cancer

70 enrolled